NasdaqGM - Nasdaq Real Time Price USD
Fulgent Genetics, Inc. (FLGT)
At close: November 15 at 4:00 PM EST
After hours: November 15 at 6:51 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
277,761.00
289,213.00
618,968.00
992,584.00
421,712.00
Cost of Revenue
177,166.00
184,757.00
252,067.00
215,533.00
89,807.00
Gross Profit
100,595.00
104,456.00
366,901.00
777,051.00
331,905.00
Operating Expense
189,265.00
179,751.00
185,399.00
101,098.00
41,747.00
Operating Income
-88,670.00
-75,295.00
181,502.00
675,953.00
290,158.00
Net Non Operating Interest Income Expense
29,658.00
21,444.00
5,498.00
1,347.00
1,526.00
Other Income Expense
-130,095.00
-120,234.00
-2,975.00
--
--
Pretax Income
-189,107.00
-174,085.00
184,025.00
677,300.00
291,684.00
Tax Provision
-17,143.00
1,154.00
42,102.00
174,795.00
72,532.00
Earnings from Equity Interest Net of Tax
--
--
--
3,734.00
-4,842.00
Net Income Common Stockholders
-164,969.00
-167,825.00
143,403.00
507,364.00
214,310.00
Diluted NI Available to Com Stockholders
-164,969.00
-167,825.00
143,403.00
507,364.00
214,310.00
Basic EPS
-5.52
-5.63
4.76
17.25
9.44
Diluted EPS
-5.52
-5.63
4.63
16.38
8.91
Basic Average Shares
30,013.50
29,784.00
30,097.00
29,408.00
22,694.00
Diluted Average Shares
30,013.50
29,784.00
30,964.00
30,976.00
24,056.00
Total Operating Income as Reported
-208,904.00
-195,529.00
178,527.00
675,953.00
290,158.00
Total Expenses
366,431.00
364,508.00
437,466.00
316,631.00
131,554.00
Net Income from Continuing & Discontinued Operation
-164,969.00
-167,825.00
143,403.00
507,364.00
214,310.00
Normalized Income
-46,474.64
-72,840.14
145,702.68
507,364.00
214,310.00
Interest Income
28,823.00
21,444.00
5,498.00
1,347.00
1,526.00
Net Interest Income
29,658.00
21,444.00
5,498.00
1,347.00
1,526.00
EBIT
-104,814.00
-75,295.00
181,502.00
675,953.00
290,158.00
EBITDA
-79,545.00
-49,152.00
214,164.00
686,957.00
293,120.00
Reconciled Cost of Revenue
159,828.00
166,459.00
225,902.00
206,237.00
86,845.00
Reconciled Depreciation
25,269.00
26,143.00
32,662.00
11,004.00
2,962.00
Net Income from Continuing Operation Net Minority Interest
-164,969.00
-167,825.00
143,403.00
507,364.00
214,310.00
Total Unusual Items Excluding Goodwill
-130,307.00
-120,234.00
-2,975.00
--
--
Total Unusual Items
-130,307.00
-120,234.00
-2,975.00
--
--
Normalized EBITDA
50,762.00
71,082.00
217,139.00
686,957.00
293,120.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-11,812.64
-25,249.14
-675.33
--
--
12/31/2020 - 9/29/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MEDP Medpace Holdings, Inc.
310.63
-7.23%
GH Guardant Health, Inc.
29.11
-3.64%
MYGN Myriad Genetics, Inc.
15.25
-2.74%
EXAS Exact Sciences Corporation
49.33
-3.14%
TWST Twist Bioscience Corporation
36.89
-5.31%
IDXX IDEXX Laboratories, Inc.
420.91
-0.65%
CSTL Castle Biosciences, Inc.
28.10
-8.86%
CDNA CareDx, Inc
21.17
-1.76%
PSNL Personalis, Inc.
3.8900
-9.53%
VCYT Veracyte, Inc.
35.94
-2.97%